Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming.
Actins
/ genetics
CRISPR-Cas Systems
/ genetics
Cell Line, Tumor
Cellular Reprogramming
/ genetics
Extracellular Vesicles
/ metabolism
Fibroblasts
/ metabolism
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Lung
/ metabolism
Neoplasm Invasiveness
/ genetics
Neoplasm Metastasis
Osteosarcoma
/ genetics
Receptor, Transforming Growth Factor-beta Type I
/ antagonists & inhibitors
extracellular vesicles
lung fibroblasts
osteosarcoma
tumor microenvironment
tumor-host interactions
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Jul 2020
30 Jul 2020
Historique:
received:
09
07
2020
revised:
23
07
2020
accepted:
29
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Tumor-secreted extracellular vesicles (EVs) have been identified as mediators of cancer-host intercellular communication and shown to support pre-metastatic niche formation by modulating stromal cells at future metastatic sites. While osteosarcoma, the most common primary malignant bone tumor in children and adolescents, has a high propensity for pulmonary metastases, the interaction of osteosarcoma cells with resident lung cells remains poorly understood. Here, we deliver foundational in vitro evidence that osteosarcoma cell-derived EVs drive myofibroblast/cancer-associated fibroblast differentiation. Human lung fibroblasts displayed increased invasive competence, in addition to increased α-smooth muscle actin expression and fibronectin production upon EV treatment. Furthermore, we demonstrate, through the use of transforming growth factor beta receptor 1 (TGFBR1) inhibitors and CRISPR-Cas9-mediated knockouts, that TGFβ1 present in osteosarcoma cell-derived EVs is responsible for lung fibroblast differentiation. Overall, our study highlights osteosarcoma-derived EVs as novel regulators of lung fibroblast activation and provides mechanistic insight into how osteosarcoma cells can modulate distant cells to potentially support metastatic progression.
Identifiants
pubmed: 32751693
pii: ijms21155451
doi: 10.3390/ijms21155451
pmc: PMC7432951
pii:
doi:
Substances chimiques
ACTA2 protein, human
0
Actins
0
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Natl Cancer Inst. 2014 Feb;106(2):djt369
pubmed: 24511106
J Biol Chem. 2007 May 18;282(20):14984-91
pubmed: 17371880
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
Mol Cancer Res. 2018 Jul;16(7):1196-1204
pubmed: 29636362
Cancer Res. 2002 Oct 1;62(19):5543-50
pubmed: 12359766
Oncoimmunology. 2020 Apr 12;9(1):1747677
pubmed: 32313728
J Bone Miner Res. 2013 Apr;28(4):838-47
pubmed: 23169460
Cancers (Basel). 2019 Jun 05;11(6):
pubmed: 31195680
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Oncotarget. 2016 Jul 12;7(28):43570-43587
pubmed: 27259278
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
J Extracell Vesicles. 2019 Apr 14;8(1):1599680
pubmed: 31044053
Oncogene. 2019 Jul;38(28):5566-5579
pubmed: 31147602
Bioinformatics. 2015 Apr 1;31(7):1120-3
pubmed: 25414360
Nat Commun. 2017 May 05;8:15178
pubmed: 28474669
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
J Exp Clin Cancer Res. 2016 Jul 16;35(1):113
pubmed: 27421768
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Cells. 2020 Jan 17;9(1):
pubmed: 31963599
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
J Pathol. 1998 Jul;185(3):284-9
pubmed: 9771482
Carcinogenesis. 2020 Jul 10;41(5):666-677
pubmed: 31294446
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Oncotarget. 2015 Jun 10;6(16):14413-27
pubmed: 26015407
Oncogene. 2015 Jan 15;34(3):290-302
pubmed: 24441045
Cancer Treat Rev. 2014 May;40(4):523-32
pubmed: 24345772
Biochem Biophys Res Commun. 2018 Jun 2;500(2):170-176
pubmed: 29626470
J Exp Clin Cancer Res. 2018 Oct 3;37(1):242
pubmed: 30285793
J Clin Med. 2016 Nov 03;5(11):
pubmed: 27827889
Cancer Cell. 2019 Jan 14;35(1):33-45.e6
pubmed: 30645975
Int J Cell Biol. 2012;2012:676731
pubmed: 22505933
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Sci Rep. 2015 Oct 21;5:15338
pubmed: 26486848
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Nat Commun. 2015 May 13;6:7164
pubmed: 25968605
Front Bioeng Biotechnol. 2016 Feb 12;4:12
pubmed: 26904541
Transl Oncol. 2014 Jun 17;7(3):331-40
pubmed: 25180057
Transl Oncol. 2017 Jun;10(3):419-430
pubmed: 28448958
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Clin Cancer Res. 2017 Jul 15;23(14):3721-3733
pubmed: 28053020
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3725-30
pubmed: 21321210
PLoS One. 2013 Sep 10;8(9):e74045
pubmed: 24040160
Clin Cancer Res. 2014 Oct 1;20(19):5097-112
pubmed: 25107916
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394